Search
Contactez-nous Suivez-nous sur Twitter En francais English Language
 

De la Théorie à la pratique











Freely subscribe to our NEWSLETTER

Newsletter FR

Newsletter EN

Vulnérabilités

Unsubscribe

Minerva Releases First Enterprise-Grade Malware Vaccination Solution for Endpoint Security

September 2017 by Marc Jacob

Minerva announced the release of the industry’s first Endpoint Malware Vaccination module for enterprises. As part of their ground-breaking Anti-Evasion Platform, this new tool helps simulate infection markers across enterprise endpoints to deceive malware into believing it has already infected the system. This unique approach allows Minerva’s customers to prevent infections even if other defensive capabilities were unable to block the attack.

Building upon its core capability to deceive malware into inaction, Minerva has taken the concept of vaccination beyond simply a “cool idea” for lab environments and allowed this technique to be deployed at an enterprise level to expand the endpoint defender’s arsenal. Key benefits of the new Endpoint Malware Vaccination tool include:

• Reduced detection time– By using Minerva to simulate the infection marker, the organization is not only alerted when malware attempts to access the marker, but also automatically blocks the attack.
• Contain attacks automatically – By deploying infection markers across all Minerva-protected endpoints, the enterprise can prevent the corresponding malware variants from spreading, with minimal human intervention.
• Collect forensics details about malware that was prevented by the vaccination to enrich threat intelligence.

Minerva was recently granted a patent for their technology layer that forms the Anti-Evasion Platform. The addition of Endpoint Malware Vaccination to Minerva’s solution builds upon this patent and reinforces the unique and innovative way in which the company protects against malware designed to evade existing security tools.




See previous articles

    

See next articles